Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr0.58
kr0.02(3.45%)
At close: 4:00 PM EDT
kr0.58
kr0.02(3.45%)
Day’s Range― - ―
52-Week Rangekr0.56 - kr2.42
Previous CloseN/A
Volume49.06K
Average Volume (3M)12.79K
Market Cap
kr64.08M
Enterprise Valuekr46.48
Total Cash (Recent Filing)kr16.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding110,476,940
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and meaningful equity reduce near-term solvency risk and give management flexibility to fund clinical work or seek strategic partnerships without immediate refinancing pressure. This bolsters runway and bargaining power during the pre-commercial development phase.
Niche Clinical Product FocusA focused offering for continuous lung monitoring in preterm infants targets a high‑value, specialized clinical niche with clear unmet needs. If clinical validation succeeds, this can create durable adoption among NICUs, high switching costs, and defensible positioning versus generalist monitoring tools.
Controlled Cash BurnOperating losses and negative cash flow persist, but they have not accelerated materially, suggesting disciplined spending. Stable burn rates improve predictability of funding needs and increase the chance management can bridge to key clinical milestones without urgent distress financing.
Bears Say
No Meaningful RevenueSustained lack of revenue indicates the product is pre‑commercial or not yet adopted, meaning business viability depends on future clinical/regulatory success and funding. Without revenue, the company faces structural execution risk and limited ability to self‑fund growth or scale operations.
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow require ongoing financing, increasing dilution or creditor dependence over time. This constrains investment in trials, regulatory work, and commercialization, and raises execution risk if capital markets or fundraising conditions tighten.
Limited Organizational ResourcesA very small team limits internal capacity to run simultaneous clinical studies, manage regulatory submissions, and build commercial infrastructure. This increases reliance on external partners and may slow time‑to‑market and adoption, impairing the company’s ability to scale in the medium term.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.56 and its highest was kr2.42 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr64.08M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is Aug 20, 2026 which is in 16 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on May 19, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.044.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 110,476,940 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.863%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. This device facilitates ongoing lung function monitoring and generates immediate alerts for critical, life-threatening complications. It achieves this by accurately tracking changes in lung volume and oxygen gas concentration. The ultimate goal of NEOLA is to enhance intensive care and promote healthier outcomes for infants born preterm. The company, formerly known as GPX Medical AB, officially changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was established in 2016 and is headquartered in Lund, Sweden.
Technical Analysis
―
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Nosa Plugs AB
―
Arcoma AB
―